Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24N2O5.2H2O |
Molecular Weight | 384.4241 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O
InChI
InChIKey=MZYVOFLIPYDBGD-MLZQUWKJSA-N
InChI=1S/C18H24N2O5.2H2O/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13;;/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25);2*1H2/t12-,14-,15-;;/m0../s1
Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 |
1.94 nM [IC50] | ||
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15236580 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VASOTEC Approved UseHypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.), Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive., Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials)., Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.) Launch Date1985 |
|||
Palliative | VASOTEC Approved UseHypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.), Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive., Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials)., Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.) Launch Date1985 |
|||
Palliative | VASOTEC Approved UseHypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.), Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive., Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials)., Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Head and Neck Angioedema.) Launch Date1985 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44.27 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
37.61 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
372.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
24.73 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29050316 |
5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ENALAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
22.5 mg 1 times / day multiple, oral (mean) Recommended Dose: 22.5 mg, 1 times / day Route: oral Route: multiple Dose: 22.5 mg, 1 times / day Sources: |
unhealthy, adult n = 276 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 276 Sources: |
Disc. AE: Pruritus, Glossitis... AEs leading to discontinuation/dose reduction: Pruritus (grade 1-3, 0.7%) Sources: Glossitis (grade 1-4, 0.4%) Dry cough (all grades, 1.1%) |
10 mg 1 times / day single, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: single Dose: 10 mg, 1 times / day Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
healthy, mean age 32.4 years n = 51 Health Status: healthy Age Group: mean age 32.4 years Sex: M+F Population Size: 51 Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
Disc. AE: Dysphagia, Hypotension... AEs leading to discontinuation/dose reduction: Dysphagia (grade 1-2, 2%) Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40Hypotension (grade 1-2, 2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry cough | all grades, 1.1% Disc. AE |
22.5 mg 1 times / day multiple, oral (mean) Recommended Dose: 22.5 mg, 1 times / day Route: oral Route: multiple Dose: 22.5 mg, 1 times / day Sources: |
unhealthy, adult n = 276 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 276 Sources: |
Pruritus | grade 1-3, 0.7% Disc. AE |
22.5 mg 1 times / day multiple, oral (mean) Recommended Dose: 22.5 mg, 1 times / day Route: oral Route: multiple Dose: 22.5 mg, 1 times / day Sources: |
unhealthy, adult n = 276 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 276 Sources: |
Glossitis | grade 1-4, 0.4% Disc. AE |
22.5 mg 1 times / day multiple, oral (mean) Recommended Dose: 22.5 mg, 1 times / day Route: oral Route: multiple Dose: 22.5 mg, 1 times / day Sources: |
unhealthy, adult n = 276 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 276 Sources: |
Dysphagia | grade 1-2, 2% Disc. AE |
10 mg 1 times / day single, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: single Dose: 10 mg, 1 times / day Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
healthy, mean age 32.4 years n = 51 Health Status: healthy Age Group: mean age 32.4 years Sex: M+F Population Size: 51 Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
Hypotension | grade 1-2, 2% Disc. AE |
10 mg 1 times / day single, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: single Dose: 10 mg, 1 times / day Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
healthy, mean age 32.4 years n = 51 Health Status: healthy Age Group: mean age 32.4 years Sex: M+F Population Size: 51 Sources: Page: nda/2013/204308Orig1s000MedR.pdf - p.40 |
PubMed
Title | Date | PubMed |
---|---|---|
Barnidipine. | 2001 |
|
Perindopril: an updated review of its use in hypertension. | 2001 |
|
The role of angiotensin II receptor antagonists in the management of diabetes. | 2001 |
|
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. | 2001 |
|
Modulation of the renin-angiotensin system may alter the adrenocortical regeneration. | 2001 |
|
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). | 2001 Apr |
|
Angiotensin-converting enzyme inhibitors and AT1-receptor antagonist restore nitric oxide synthase (NOS) activity and neuronal NOS expression in the adrenal glands of spontaneously hypertensive rats. | 2001 Apr |
|
Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. | 2001 Apr |
|
Solid-phase extraction and high-performance liquid chromatography applied to the determination of quinapril and its metabolite quinaprilat in urine. | 2001 Apr |
|
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. | 2001 Apr |
|
The effects of angiotensin-II on lipolysis in humans. | 2001 Apr |
|
Different potentiating effects of imidapril and enalapril on kaolin-induced writhing reaction in mice. | 2001 Apr 13 |
|
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. | 2001 Apr 9 |
|
A simple HPLC method for quantitation of enalaprilat. | 2001 Feb |
|
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples]. | 2001 Feb |
|
On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy. | 2001 Feb |
|
Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. | 2001 Feb |
|
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. | 2001 Feb |
|
Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. | 2001 Feb |
|
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. | 2001 Feb |
|
Mechanisms underlying renoprotection during renin-angiotensin system blockade. | 2001 Feb |
|
Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. | 2001 Feb 16 |
|
Control of renin secretion from adrenal gland in transgenic Ren-2 and normal rats. | 2001 Feb 28 |
|
Volume-weighted mean nuclear volume and numerical nuclear density in the cardiomyocyte following enalapril and verapamil treatment. | 2001 Jan |
|
Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. | 2001 Jan |
|
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. | 2001 Jan |
|
Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. | 2001 Jul |
|
IgA nephropathy and inhibitors of the renin angiotensin system: is reduction in proteinuria adequate proof of efficacy? | 2001 Jul |
|
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. | 2001 Jul |
|
The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. | 2001 Jun |
|
Comparison of effects of losartan versus enalapril on fibrinolysis and coagulation in patients with acute myocardial infarction. | 2001 Jun 15 |
|
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs. | 2001 Mar |
|
A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. | 2001 Mar |
|
Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. | 2001 Mar |
|
Management of asymptomatic left ventricular dysfunction. | 2001 Mar |
|
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors? | 2001 Mar |
|
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. | 2001 Mar |
|
Strict volume control normalizes hypertension in peritoneal dialysis patients. | 2001 Mar |
|
Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. | 2001 Mar |
|
Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? | 2001 Mar-Apr |
|
A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. | 2001 May |
|
Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats. | 2001 May |
|
The bladder angiotensin system in female rats: response to infusions of angiotensin I and the angiotensin converting enzyme inhibitor enalaprilat. | 2001 May |
|
Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. | 2001 May |
|
Improved survival with simendan after experimental myocardial infarction in rats. | 2001 May 11 |
|
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. | 2001 May 17 |
|
Racial differences in the response to drugs--pointers to genetic differences. | 2001 May 3 |
|
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. | 2001 May 3 |
|
Effect of column temperature on the behaviour of some angiotensin converting enzyme inhibitors during high-performance liquid chromatographic analysis. | 2001 May 5 |
|
The effect of enalapril on advanced diabetic nephropathy in African-American females. | 2001 Spring-Summer |
Patents
Sample Use Guides
Hypertension: The recommended initial dose in patients not on diuretics is 5 mg once a day.
Dosage Adjustment in Hypertensive Patients with Renal Impairment: The usual dose of enalapril is recommended for patients with a creatinine clearance >30 mL/min (serum
creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≤30 mL/min (serum creatinine ≥3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.
Heart Failure: The recommended initial dose is 2.5 mg. The recommended dosing range is 2.5 to 20 mg given twice a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124597
Primary cultures of human proximal tubular cells (PTC) and renal cortical fibroblasts (CF) were exposed for 24 h to CyA in the presence or absence of enalaprilat (enalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat). Enalaprilat completely reversed the stimulatory effects of CyA on CF collagen synthesis (CyA + enalaprilat 6.40 +/- 0.50% vs. CyA alone 8.33 +/- 0.56% vs. control 6.57 +/- 0.62% vs. enalaprilat alone 5.55 +/- 0.93%, p < 0.05) and PTC secretion of TGFbeta1 (0.71 +/- 0.11, 1.13 +/- 0.09, 0.89 +/- 0.07, and 0.67 +/- 0.09 ng/mg protein/day, respectively, p < 0.05).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
348
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
||
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GV0O7ES0R3
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
59877
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
C47510
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
GV0O7ES0R3
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
6917719
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
1006
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
100000080222
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
U-52
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
DTXSID901004963
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
760053
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
84680-54-6
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
m4893
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL577
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
3829
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB09477
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
4786
Created by
admin on Fri Dec 15 15:23:58 GMT 2023 , Edited by admin on Fri Dec 15 15:23:58 GMT 2023
|
PRIMARY | |||
|
D015773
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
6332
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
Enalaprilat
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY | |||
|
1235274
Created by
admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD